Market Intelligence, Clinical Progress, and High-Purity Reagents for Gaucher & Parkinson's Disease Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for GBA1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen (Wild-Type) | GBA1 Full-Length Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. HEK293 Expressed (Native Glycosylation). Sequence Verified. |
View GBA1 Products |
| Antigen (Pathogenic Mutants) | GBA1 N370S, L444P, R463C Mutant Proteins Critical for chaperone screening and enzymatic activity assays. |
View GBA1 Products |
| Gene Delivery | GBA1 Lentivirus Premade Particles Full-length ORF for stable cell line construction in iPSC-derived macrophages or neuronal models. |
View GBA1 Products |
| Benchmark Ab | Anti-GBA1 (Clone 8E4 Reference Sequence) Recombinant positive control for Western blot and immunofluorescence. |
View GBA1 Products |
| Validator | GBA1 siRNA Set For knockdown verification in lysosomal trafficking assays. |
View GBA1 Products |
| Related Target: LRRK2 | LRRK2 Synergistic pathway in Parkinson's disease progression; point of convergence with GBA1 in lysosomal dysfunction. |
View LRRK2 Products |
| Related Target: SNCA | SNCA (Alpha-Synuclein) Downstream Parkinson's pathology marker; GBA1 activity directly modulates aggregation. |
View SNCA Products |
| Related Target: GBA2 | Non-Lysosomal Glucosidase Critical off-target for selective inhibitor design; required for counter-screening. |
View GBA2 Products |
| Related Target: PSAP | Prosaposin / Saposin C Essential cofactor for GBA1 enzymatic activity; co-crystal structure studies. |
View PSAP Products |
| Related Target: SCARB2 | LIMP-2 / SCARB2 Receptor Mediates GBA1 lysosomal targeting; trafficking assay component. |
View SCARB2 Products |
Critical Assay Challenges & TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Pharmacological Chaperone Screening (Thermal Stability Shift) | Pathogenic Mutant Panel (N370S, L444P, R463C) with >95% purity; Sequence Verified; Stable at physiological pH |
| Enzymatic Activity Measurement (4-MUG Hydrolysis) | Wild-Type GBA1 with native glycosylation pattern (HEK293 expressed); Theoretical MW confirmed by Mass Spec |
| Off-Target Selectivity (GBA2 vs GBA1) | Human GBA2 Ortholog Protein available; Strict sequence verification to ensure isoform specificity |
| Lysosomal Trafficking Validation | GBA1 Lentivirus for stable expression in HEK293 or SH-SY5Y cells; Co-transfection with SCARB2 available |
| CNS Penetration Model (Blood-Brain Barrier) | High-concentration protein formulations for micro-dialysis studies; Endotoxin Controlled (<0.1 EU/ug available) |
| Lack of Controls | Clinical Benchmark Antibodies included for assay standardization |
| False Positives | Validated siRNA included for specificity checks in cell-based models |
Live GBA1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
- ➤ View Active Clinical Trials (GBA1)
- ➤ View Active Gaucher Clinical Trials
- ➤ View Active Parkinson's Trials (GBA1-targeting)
- ➤ Latest Chaperone Research
- ➤ Latest Resistance Research
- ➤ Recent Patent Filings
Global Clinical Landscape & Future Outlook
The GBA1 therapeutic landscape is bifurcating between established Enzyme Replacement Therapies (ERT) for Gaucher disease and emerging small-molecule approaches targeting Parkinson's disease. First-generation ERTs (Imiglucerase, Velaglucerase) dominate the Gaucher market but face biosimilar competition and limitations in CNS penetration. The next wave of R&D focuses on CNS-penetrant small molecule chaperones (pharmacological chaperones) and gene therapy vectors (AAV9-GBA1) to address the Parkinson's population carrying GBA1 mutations. As first-generation therapies reach the clinic, the next wave of R&D is targeting allosteric modulation to rescue mutant GBA1 activity. As precision medicine advances, drug developers require mutant-specific proteins and sophisticated lysosomal targeting assays to differentiate candidates based on blood-brain barrier penetration and mutant enzyme stabilization capabilities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Enzyme Replacement (ERT) | Sanofi (Cerezyme), Takeda (VPRIV), Pfizer/Protalix (Elelyso) | Type 1 Gaucher Disease | Immunogenicity testing with Endotoxin-controlled (<0.1 EU/ug) protein; Enzyme activity profiling |
| Small Molecule Chaperones | Bial, Gain Therapeutics, Amicus, Prevail Therapeutics (Lilly), Denali Therapeutics | Parkinson's Disease, Neuronopathic Gaucher | Allosteric activation assays, Thermal Shift Assay (Need N370S/L444P mutant proteins >95% purity) |
| Gene Therapy (AAV) | Voyager Therapeutics, Prevail/Lilly, Avrobio, Novartis | Parkinson's Disease (GBA1-PD), Gaucher Disease | Expression level validation using GBA1 Lentivirus in neuronal cell models |
| Substrate Reduction Therapy | Sanofi (Cerdelga), Actelion (Zavesca) | Type 1 Gaucher Disease | Enzymatic activity assays (Need WT GBA1 with native glycosylation) |
Related Targets and Synergistic Pathways
- LRRK2: GBA1 and LRRK2 converge on lysosomal dysfunction pathways. Combining GBA1 activators with LRRK2 inhibitors is a promising combination strategy for Parkinson's disease.
- SNCA (Alpha-synuclein): GBA1 deficiency directly promotes alpha-synuclein aggregation. Measuring SNCA clearance is a key downstream readout for GBA1-targeted therapies.
- GBA2 (Non-lysosomal Glucosylceramidase): A critical off-target for selectivity screening; inhibition of GBA2 can cause spermatogenesis defects and neurotoxicity.
- PSAP (Prosaposin/Saposin C): Essential cofactor for GBA1 enzymatic activity. PSAP mutations mimic Gaucher symptoms; co-crystal studies require PSAP protein.
- SCARB2 (LIMP-2): The lysosomal trafficking receptor for GBA1. Critical for ERT uptake studies and viral entry research (EV71).